1 Product identity
Ingredient risk
Contains restricted ingredients
St. John's Wort 300 mg
BrandRadiance→Botanical Capsule 5 ingredients 1 banned 1 caution DSLD #45930Net contents: 100 Capsule(s)
Target: Adults and Children 4 years and above
DSLD entry: 2015-05-22
2 Ingredients (5)
IngredientGroupSafety
GelatinGelatin—
Ingredient amounts require the full DSLD label. View full label at NIH DSLD →
⛔ Contains an ingredient banned in ≥1 country
St. John's Wort 🇫🇷 🇯🇵 🇰🇷 — dards. Drug interaction warnings required [2]. || France :: Banned from sale as a supplement (2000) due to drug interaction concerns [3]. ||
⚠️ Use with caution — restricted in some markets
Magnesium — Severe deficiency (<0.50 mmol/L) causes secondary hypocalcemia and hypokalemia that will not correct until magnesium is repleted first [1].
3 Safety cross-reference
St. John's Wort — Banned in ≥1 country
⚠ MAJOR CYP3A4 INDUCER — interacts with >50% of drugs
⚠ Serotonin syndrome with SSRIs
Calcium — Conditionally Safe
⚠ Cardiovascular risk debated >1,000 mg/day
⚠ Kidney stones
Silicon — Generally Safe
⚠ Very low toxicity
Magnesium — Use with Caution
⚠ Diarrhea (especially oxide)
⚠ Accumulates in renal impairment
4 Label claims
• All Other
• Structure/Function
5 Data source
DSLD ID45930
Full labelView at NIH DSLD →
SourceOffice of Dietary Supplements, NIH
Market statusOn market
Entry date2015-05-22
6 More from Radiance
View Radiance Safety Scorecard → 7 products
Bee Pollen Complex 1000 PlusEvening Primrose Oil 1000 mgFlaxseed Oil 1200 mgLycopene 10 mgOriginal Papaya EnzymeSilymarin Milk Thistle 175 mg7 Cite this page
Vancouver
Pkhakadze G. St. John's Wort 300 mg — product analysis [Internet]. Tbilisi: Public Health Institute of Georgia; 2026 [cited 2026 Oct 20]. Available from: https://supplement.ge/products/st-johns-wort-300-mg-45930/
CC BY 4.0. Product data from NIH DSLD; safety analysis by SupplementIndex.
GP
Analyzed by SupplementIndex
PHIG · Editor-in-Chief: Prof. Giorgi Pkhakadze, MD, MPH, PhD
Product data sourced from the NIH Dietary Supplement Label Database (DSLD). Safety cross-referencing by SupplementIndex. This analysis is for informational purposes only. For corrections: info@accreditation.ge.
Publisher: PHIG
Publisher: PHIG